PARTNERSHIPS
2006 Sandoz Collaboration
Our most recent collaboration with Sandoz, announced in July 2006, supports the development, manufacture and commercialization of three generic and follow-on versions of major marketed drugs and expands our existing partnership for M-Enoxaparin to include the European Union. Included in this collaboration are the product candidates M356, M178 and M249.
2003 Sandoz Collaboration
Our first partnership with Sandoz, established in November 2003, is for the development, manufacture and commercialization of M-Enoxaparin, a technology-enabled generic version of Lovenox, in the United States.